Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00798070 (A Randomised Phase 3 Study Comparing Biweekly and Tailored Epirubicin + Cyclophosphamide Followed by Biweekly Tailored Docetaxel Versus Three Weekly Epirubicin + Cyclophosphamide + 5-fluorouracil Followed by Docetaxel in Lymph Node Positive or High Risk Lymph Node Negative Breast Cancer Patients), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomised Phase 3 Study Comparing Biweekly and Tailored Epirubicin + Cyclophosphamide Followed by Biweekly Tailored Docetaxel Versus Three Weekly Epirubicin + Cyclophosphamide + 5-fluorouracil Followed by Docetaxel in Lymph Node Positive or High Risk Lymph Node Negative Breast Cancer Patients
Who cites it
10 citing papers in PubMed.
- Trial
- Surgery-first versus neoadjuvant chemotherapy in stage I (cT1c) triple-negative breast cancer: A critical reappraisal.Breast (Edinburgh, Scotland) · 2026Review
- Mapping supportive-care evidence for febrile neutropenia prevention in breast cancer chemotherapy: a bibliometric analysis of long-acting G-CSF prophylaxis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Case Report: Complete remission of thymic carcinoma using dose-dense chemotherapy.Frontiers in oncology · 2026Article
- Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based study.The Lancet regional health. Europe · 2025Article
- Major systemic infection following breast cancer surgery and oncological outcomes.The British journal of surgery · 2025Article
- Article
- Dose-dense adjuvant chemotherapy for high-risk early breast cancer: its role in the era of personalised oncology.Gland surgery · 2025Article
- Revisiting the Cardiac Safety of Dose-Dense Chemotherapy: Encouraging Outcomes From Long-Term Follow-Up.International journal of heart failure · 2025Article
- Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trial.The Lancet regional health. Europe · 2025Article
Corrections and comments
- Commented on by
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.